Siemens Fonds Invest GmbH Buys 8,177 Shares of Gilead Sciences, Inc. $GILD

Siemens Fonds Invest GmbH raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 15.8% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 59,922 shares of the biopharmaceutical company’s stock after acquiring an additional 8,177 shares during the quarter. Siemens Fonds Invest GmbH’s holdings in Gilead Sciences were worth $7,381,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of GILD. Quattro Advisors LLC bought a new position in Gilead Sciences during the fourth quarter valued at about $26,000. Ares Financial Consulting LLC bought a new position in Gilead Sciences during the fourth quarter valued at about $28,000. Financial Consulate Inc. raised its holdings in Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 109 shares in the last quarter. North Star Investment Management Corp. raised its holdings in Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 86 shares in the last quarter. Finally, BOCHK Asset Management Ltd bought a new position in Gilead Sciences during the fourth quarter valued at about $31,000. 83.67% of the stock is currently owned by institutional investors.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the transaction, the chief executive officer directly owned 617,567 shares in the company, valued at approximately $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the transaction, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 68,000 shares of company stock worth $8,930,150. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Up 2.4%

Gilead Sciences stock opened at $127.23 on Wednesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The business’s 50-day simple moving average is $132.61 and its 200-day simple moving average is $134.32. The firm has a market capitalization of $157.96 billion, a PE ratio of 17.33 and a beta of 0.31. Gilead Sciences, Inc. has a 52 week low of $104.46 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is presently 44.69%.

Analysts Set New Price Targets

Several equities analysts have weighed in on GILD shares. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a report on Wednesday, May 20th. Rothschild & Co Redburn cut their target price on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Needham & Company LLC restated a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a report on Monday, February 23rd. Finally, Morgan Stanley cut their target price on Gilead Sciences from $175.00 to $168.00 in a report on Friday, May 8th. Twenty-five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $158.41.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The FDA accepted Gilead’s application for once-weekly oral Yeztugo (lenacapavir) for HIV prevention, advancing a potential new long-acting PrEP option and opening a possible new growth driver for the company. FDA Accepts Gilead’s Filing for Weekly Oral Yeztugo for HIV Prevention
• Positive Sentiment: Cantor Fitzgerald reaffirmed its Overweight rating and set a $155 price target, signaling continued analyst confidence in upside from current levels. Benzinga report on Cantor Fitzgerald rating
• Neutral Sentiment: Two Gilead insiders, including CFO Andrew D. Dickinson and Johanna Mercier, sold shares under pre-arranged 10b5-1 plans. The sales were disclosed normally and do not appear to signal an abrupt change in outlook, but they can still weigh on sentiment. SEC filing for Andrew D. Dickinson sale SEC filing for Johanna Mercier sale
• Neutral Sentiment: Recent reports noted GILD had previously dipped modestly in the prior session, but the stock’s latest move appears tied more to the FDA milestone and analyst support than to broader market action. Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.